Q-omics provides the consensus-scored TAF10 profile across patient tissues and cancer cell-line models. TAF10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TAF10 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TAF10 protein abundance shows 19,748 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where TAF10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF10 survival associations across molecular data types. TAF10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF10 RNA expression–survival associations across cancer types. High TAF10 expression shows unfavorable associations in KIRC, ACC, LIHC and LUAD, but favorable associations in SCLC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TAF10 RNA expression.
This table summarizes TAF10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TAF10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF10 shows higher tumor expression in KIRC, KIRP, COAD, LIHC, STAD and HNSC. The KIRC box plot shows higher TAF10 RNA expression in tumor versus normal tissue (log2 FC = +0.668, t-test p < 0.001).
This table shows molecular features associated with TAF10 in patient tissues and cancer cell lines. In patient samples, TAF10 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
